DUBLIN–(BUSINESS WIRE)–The “Licensing Deals in Biotechnology 2020-2025” report has been added to ResearchAndMarkets.com’s offering.
Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully revised and updated, the report provides details of licensing deals from 2020 to 2025.
Licensing Deals in Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2020
- Browse licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms – upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents – insights into deal structures
- Due diligence – assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Licensing Deals in Biotechnology is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.
Licensing Deals in Biotechnology includes:
- Trends in licensing dealmaking in the biopharma industry
- Overview of licensing deal structure
- Directory of licensing deal records covering pharmaceutical and biotechnology
- The leading licensing deals by value
- Most active licensing dealmakers
- The leading licensing partnering resources
In Licensing Deals in Biotechnology, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Licensing Deals in Biotechnology provides comprehensive access to available records for licensing deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Featured
- 1cBio
- 2seventy bio
- 3B Pharmaceuticals
- 3D Medicines
- 3rd People’s Hospital of Shenzhen
- 3SBio
- 3T Biosciences
- 4D Molecular Therapeutics
- 9 Meters Biopharma
- 10X Genomics
- 23andMe
- 48Hour Discovery
- 180 Life Sciences
- A2 Biotherapeutics
- Aadi Bioscience
- Aardvark Therapeutics
- Aarhus University
- Aarvik Therapeutics
- AAVnerGene
- AazeinTx
- AB2 Bio
- Abbvie
- Abcam
- AbCellera Biologics
- AbelZeta Pharma
- Abeona Therapeutics
- Abilita Therapeutics
- Abintus Bio
- ABL Bio
- Ablexis
- Abliva
- Abound Bio
- Aboundbio
- Abpro
- AbSci
- AbTherx
- ABT Innovations
- ABVC BioPharma
- ABX
- ACADIA Pharmaceuticals
- AC Bioscience
- Accelerated Biosciences
- Accelerate Technologies
- AccuGenomics
- Accurus Biosciences
- AccuStem Sciences
- ACEA Therapeutics
- AcedrA BioPharmaceuticals
- and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/cpi6fs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900